Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
Leishmaniasis is a major health problem and it is estimated that 12 million people are currently infected. A vaccine which could cross-protect people against different Leishmania spp. would facilitate control of this disease as more than one species of Leishmania may be present. In this study the ability of a DNA vaccine, using the full gene sequence for L. donovani gamma glutamyl cysteine synthetase (γGCS) incorporated in the pVAX vector (pVAXγGCS), and a protein vaccine, using the corresponding recombinant L. donovani γGCS protein (LdγGCS), to protect against L. major or L. mexicana infection was evaluated. DNA vaccination gave transient protection against L. major and no protection against L. mexicana despite significantly enhancing specific antibody titres in vaccinated infected mice compared to infected controls. Vaccination with the LdγGCS protected against both species but only if the protein was incorporated into non-ionic surfactant vesicles for L. mexicana. The results of this study indicate that a L. donovani γGCS vaccine could be used to vaccinate against more than one Leishmania species but only if the recombinant protein is used.
School of Life, Sport and Social Sciences, Edinburgh Napier University, Edinburgh, UK.
S A
SA
Campbell
J
J
Alawa
B
B
Doro
F L
FL
Henriquez
C W
CW
Roberts
A
A
Nok
C B I
CB
Alawa
M
M
Alsaadi
A B
AB
Mullen
K C
KC
Carter
D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis / Q000276:immunology; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology*; D056738:Cross Protection; D000939:Epitopes; D005721:Glutamate-Cysteine Ligase / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007893:Leishmania donovani / Q000276:immunology*; D018320:Leishmania major / Q000276:immunology; D007894:Leishmania mexicana / Q000276:immunology; D054332:Leishmaniasis Vaccines / Q000235:genetics / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control*; D007898:Leishmaniasis, Visceral / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA; D022223:Vaccines, Subunit
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D000939:Epitopes; D054332:Leishmaniasis Vaccines; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D022223:Vaccines, Subunit; D005721:Glutamate-Cysteine Ligase